Valuation: TG Therapeutics, Inc.

Market Cap 8.11B 7.1B 6.54B 6.05B 11.49B 774B 11.68B 78.36B 30.72B 380B 30.45B 29.79B 1,317B P/E 2026 *
42.7x
P/E 2027 * 20.9x
Enterprise Value 8.16B 7.14B 6.58B 6.09B 11.56B 779B 11.75B 78.8B 30.89B 382B 30.62B 29.96B 1,324B EV / Sales 2026 *
8.67x
EV / Sales 2027 * 6.13x
Free-Float
88.55%
Yield 2026 *
-
Yield 2027 * -
07-07 Moderna, TG Therapeutics, Agios Pharmaceuticals Q2 Results May Face Increased Scrutiny, BofA Says MT
07-07 BofA Securities Adjusts Price Target on TG Therapeutics to $20 From $17, Maintains Underperform Rating MT
07-06 TG Therapeutics Initiates Phase 2 Trial Evaluating BRIUMVI In Patients With Treatment-Resistant Schizophrenia CI
07-06 TG Therapeutics Begins Phase 2 Trial of Briumvi in Treatment-Resistant Schizophrenia MT
06-09 TG Therapeutics, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 02:00 PM
06-09 TG Therapeutics Reports Positive Topline Phase 1 Data For Subcutaneous BRIUMVI In Patients With Myasthenia Gravis and Initiates Potential Registration Directed Randomized Phase 2 Trial CI
06-09 TG Therapeutics Begins Phase 2 Myasthenia Gravis Trial MT
06-03 TG Therapeutics Reports Positive Phase 1 Data for Subcutaneous Multiple Sclerosis Therapy MT
06-03 TG Therapeutics, Inc. Announces Positive Results From Phase 1 Trial Evaluating Subcutaneous BRIUMVI CI
06-01 TG Therapeutics announces publication of post-hoc data from the phase 3 Ultimate I & II trials in treatment naive patients with relapsing forms of MS published in Frontiers in Immunology RE
06-01 TG Therapeutics, Inc. Publishes Post-Hoc Data from Phase 3 Ultimate I and Ii Trials Evaluating Briumvi in Treatment-Naïve Patients with Relapsing Multiple Sclerosis CI
05-27 Tg Therapeutics Announces Positive Topline Results from Phase 3 Enhance Trial CI
05-27 TG Therapeutics Says Phase 3 Briumvi Trial Met Main Goal MT
1 day+3.20%
1 week+10.79%
Current month+7.50%
1 month+36.18%
3 months+70.55%
6 months+107.45%
Current year+98.12%
1 week 53.09
Extreme 53.09
59.3
1 month 43.01
Extreme 43.0126
59.3
Current year 26.76
Extreme 26.76
59.3
1 year 25.28
Extreme 25.28
59.3
3 years 6.46
Extreme 6.46
59.3
5 years 3.48
Extreme 3.48
59.3
10 years 3.32
Extreme 3.32
59.3
Manager TitleAgeSince
Chief Executive Officer 60 29/12/2011
Director of Finance/CFO 44 29/12/2011
Investor Relations Contact - 01/12/2011
Director TitleAgeSince
Chairman 60 29/12/2011
Director/Board Member 79 01/03/2012
Director/Board Member 61 15/12/2014
Date Insider Type Main position Quantity % Market Cap.
06-11Free

Director

8,325 0.0054%
06-11Free

Director

8,325 0.0054%
06-11Free

Director

8,325 0.0054%
Change 5-day change 1-year change 3-year change Capi.($)
+3.20%+10.79%+55.75%+122.87% 8.11B
+0.09%+0.25%+54.65%+168.55% 1,084B
-1.63%-1.50%+65.79%+62.43% 634B
-1.12%-4.27%+31.10%+85.82% 447B
+0.18%+2.04%+30.19%+26.51% 330B
-6.22%-3.61%+29.15%+32.09% 295B
-1.27%-0.56%+27.21%+46.39% 285B
-0.93%-1.19%-28.85%-40.38% 218B
-1.19%-2.81%+22.63%+61.80% 199B
-0.72%+2.72%+19.07%+78.15% 169B
Average -1.04%+2.96%+30.67%+64.42% 366.8B
Weighted average by Cap. -1.31%+2.49%+39.00%+84.44%

Financials

2026 *2027 *
Net sales 941M 823M 759M 702M 1.33B 89.78B 1.35B 9.09B 3.56B 44.09B 3.53B 3.45B 153B 1.24B 1.09B 1B 927M 1.76B 119B 1.79B 12B 4.7B 58.22B 4.66B 4.56B 202B
Net income 212M 186M 171M 159M 301M 20.27B 306M 2.05B 804M 9.96B 797M 780M 34.49B 470M 411M 379M 351M 666M 44.86B 677M 4.54B 1.78B 22.03B 1.76B 1.73B 76.3B
Net Debt 45.42M 39.73M 36.64M 33.9M 64.35M 4.34B 65.42M 439M 172M 2.13B 171M 167M 7.37B -492M -431M -397M -368M -698M -47B -709M -4.76B -1.86B -23.08B -1.85B -1.81B -79.95B
Logo TG Therapeutics, Inc.
TG Therapeutics, Inc. is a fully integrated, commercial stage biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its products include Ublituximab IV (anti-CD20 mAb), Ublituximab IV Simplified Dosing Schedule, Ublituximab Subcutaneous (anti-CD20 mAb), and Azer-cel. It is engaged in late-stage clinical development of BRIUMVI. BRIUMVI is an anti-CD20 monoclonal antibody that can be administered to adults with relapsing forms of multiple sclerosis (RMS) in a one-hour infusion every 24 weeks, following the starting dose. It is used for treatment of adults with clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The Company is also engaged in ULTIMATE I & II Trials Evaluating Single Agent Ublituximab in RMS. Its ENHANCE Phase 3b Trial is an ongoing, multi-center, open-label study designed to evaluate alternative dosing regimens for BRIUMVI in patients with RMS.
Employees
399
Date Price Change Volume
09/07/26 $59.06 +3.20% 1,555,261
08/07/26 $57.23 -1.43% 1,854,933
07/07/26 $58.06 +4.67% 2,105,178
06/07/26 $55.47 +4.05% 2,700,374
02/07/26 $53.31 -0.39% 3,076,369
Trader
Investor
Global
Quality
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
57.23USD
Average target price
52.14USD
Spread / Average Target
-8.89%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TGTX Stock